Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8607108 | 0.83 | TGFBR1 (0.38) | CLK1EPHB3 | |
| SCHEMBL9753674 | 0.80 | CLK1 (0.32) | CLK1 | |
| SCHEMBL9753913 | 0.77 | — | — | |
| SCHEMBL9753432 | 0.77 | CLK1 (0.36) | CLK1EPHB3 | |
| SCHEMBL9753592 | 0.76 | — | — | |
| SCHEMBL8607440 | 0.75 | CLK1 (0.37) | CLK1EPHB3 | |
| SCHEMBL8609758 | 0.73 | CLK1 (0.37) | CLK1EPHB3 | |
| SCHEMBL8608539 | 0.71 | EIF2AK4 (0.31) | CLK1 | |
| SCHEMBL8609206 | 0.68 | — | — | |
| SCHEMBL9753548 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0436831-A2 | Imidazo[1,2-a]pyridinylalkyl compounds for treatment of neurotoxic injury | G.D. Searle & Co. (US) | 1991-07-17 | — | — | EP | claimed |
| WO-1991008211-A1 | IMIDAZO[1,2-a]PYRIDINYLALKYL COMPOUNDS FOR TREATMENT OF NEUROTOXIC INJURY | G.D. SEARLE & CO. (US) | 1991-06-13 | — | — | WO | claimed |
| US-5716964-A | BRAIN DISORDERS; ANTIISCHEMIC AGENTS | G.D. SEARLE & CO. (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0436831-A2 | Imidazo[1,2-a]pyridinylalkyl compounds for treatment of neurotoxic injury | G.D. Searle & Co. (US) | 1991-07-17 | — | — | EP | disclosed |
| WO-1991008211-A1 | IMIDAZO[1,2-a]PYRIDINYLALKYL COMPOUNDS FOR TREATMENT OF NEUROTOXIC INJURY | G.D. SEARLE & CO. (US) | 1991-06-13 | — | — | WO | disclosed |